Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity
Open Access
- 1 March 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 10, 133
Abstract
Leukemia, specifically acute myeloid leukemia (AML), is a common malignancy that can be differentiated into multiple subtypes based on leukemogenic history and etiology. Although genetic aberrations, particularly cytogenetic abnormalities and mutations in known oncogenes, play an integral role in AML development, epigenetic processes have been shown as a significant and sometimes independent dynamic in AML pathophysiology. Here, we summarize how tumors evolve and describe AML through an epigenetic lens, including discussions on recent discoveries that include prognostics from epialleles, changes in RNA function for hematopoietic stem cells and the epitranscriptome, and novel epigenetic treatment options. We further describe the limitations of treatment in the context of the high degree of heterogeneity that characterizes acute myeloid leukemia.Keywords
Funding Information
- NASA (NNX14AH50G, NNX17AB26G)
- National Institutes of Health (R25EB020393, R01NS076465, R01AI125416, R01ES021006, 1R21AI129851, 1R01MH117406)
- Bill and Melinda Gates Foundation (OPP1151054)
- Leukemia and Lymphoma Society (LLS 923816, LLS-MCL-982)
This publication has 184 references indexed in Scilit:
- The Origin and Evolution of Mutations in Acute Myeloid LeukemiaCell, 2012
- The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem CellsCancer Cell, 2012
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genesJournal of Cellular Physiology, 2010
- DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid LeukemiaCancer Cell, 2010
- Linking Cell Cycle to Histone Modifications: SBF and H2B Monoubiquitination Machinery and Cell-Cycle Regulation of H3K79 DimethylationMolecular Cell, 2009
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- High-Resolution Profiling of Histone Methylations in the Human GenomeCell, 2007
- Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1Cell, 2004